Logo image of ETON

ETON PHARMACEUTICALS INC (ETON) Stock Fundamental Analysis

NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD

15.09  -0.62 (-3.95%)

After market: 15.09 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ETON. ETON was compared to 195 industry peers in the Pharmaceuticals industry. ETON may be in some trouble as it scores bad on both profitability and health. ETON is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ETON has reported negative net income.
ETON had a positive operating cash flow in the past year.
ETON had negative earnings in each of the past 5 years.
In multiple years ETON reported negative operating cash flow during the last 5 years.
ETON Yearly Net Income VS EBIT VS OCF VS FCFETON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

ETON's Return On Assets of -5.45% is fine compared to the rest of the industry. ETON outperforms 74.87% of its industry peers.
With a decent Return On Equity value of -18.74%, ETON is doing good in the industry, outperforming 73.33% of the companies in the same industry.
Industry RankSector Rank
ROA -5.45%
ROE -18.74%
ROIC N/A
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ETON Yearly ROA, ROE, ROICETON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ETON has a better Gross Margin (58.49%) than 68.21% of its industry peers.
In the last couple of years the Gross Margin of ETON has grown nicely.
The Profit Margin and Operating Margin are not available for ETON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
ETON Yearly Profit, Operating, Gross MarginsETON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

2

2. Health

2.1 Basic Checks

ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
ETON has more shares outstanding than it did 1 year ago.
ETON has more shares outstanding than it did 5 years ago.
ETON has a worse debt/assets ratio than last year.
ETON Yearly Shares OutstandingETON Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ETON Yearly Total Debt VS Total AssetsETON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

ETON has an Altman-Z score of 3.27. This indicates that ETON is financially healthy and has little risk of bankruptcy at the moment.
ETON has a better Altman-Z score (3.27) than 76.41% of its industry peers.
ETON has a Debt/Equity ratio of 1.23. This is a high value indicating a heavy dependency on external financing.
ETON has a worse Debt to Equity ratio (1.23) than 73.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Altman-Z 3.27
ROIC/WACCN/A
WACC10.01%
ETON Yearly LT Debt VS Equity VS FCFETON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.97 indicates that ETON should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.97, ETON is doing worse than 61.54% of the companies in the same industry.
ETON has a Quick Ratio of 1.43. This is a normal value and indicates that ETON is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.43, ETON is doing worse than 64.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.43
ETON Yearly Current Assets VS Current LiabilitesETON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for ETON have decreased strongly by -500.00% in the last year.
Looking at the last year, ETON shows a very strong growth in Revenue. The Revenue has grown by 40.86%.
The Revenue has been growing by 109.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)40.86%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%116.95%

3.2 Future

Based on estimates for the next years, ETON will show a very strong growth in Earnings Per Share. The EPS will grow by 90.90% on average per year.
ETON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.60% yearly.
EPS Next Y474%
EPS Next 2Y242.97%
EPS Next 3Y149.41%
EPS Next 5Y90.9%
Revenue Next Year105.03%
Revenue Next 2Y76.15%
Revenue Next 3Y61.76%
Revenue Next 5Y43.6%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ETON Yearly Revenue VS EstimatesETON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ETON Yearly EPS VS EstimatesETON Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETON. In the last year negative earnings were reported.
ETON is valuated reasonably with a Price/Forward Earnings ratio of 11.04.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ETON indicates a rather cheap valuation: ETON is cheaper than 83.08% of the companies listed in the same industry.
ETON is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.40, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 11.04
ETON Price Earnings VS Forward Price EarningsETON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ETON is valued a bit cheaper than the industry average as 74.36% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8344.5
ETON Per share dataETON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

ETON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ETON's earnings are expected to grow with 149.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y242.97%
EPS Next 3Y149.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ETON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETON PHARMACEUTICALS INC

NASDAQ:ETON (6/11/2025, 8:00:02 PM)

After market: 15.09 0 (0%)

15.09

-0.62 (-3.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04
Inst Owners49.94%
Inst Owner Change8.77%
Ins Owners5.61%
Ins Owner Change-2.6%
Market Cap404.71M
Analysts82.22
Price Target29.58 (96.02%)
Short Float %2.32%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-230.07%
Min EPS beat(2)-488.82%
Max EPS beat(2)28.68%
EPS beat(4)2
Avg EPS beat(4)-33.52%
Min EPS beat(4)-488.82%
Max EPS beat(4)394.12%
EPS beat(8)5
Avg EPS beat(8)15.47%
EPS beat(12)8
Avg EPS beat(12)14.28%
EPS beat(16)9
Avg EPS beat(16)-6.85%
Revenue beat(2)2
Avg Revenue beat(2)10.2%
Min Revenue beat(2)8.43%
Max Revenue beat(2)11.97%
Revenue beat(4)4
Avg Revenue beat(4)6.47%
Min Revenue beat(4)1.09%
Max Revenue beat(4)11.97%
Revenue beat(8)6
Avg Revenue beat(8)13.43%
Revenue beat(12)8
Avg Revenue beat(12)9.12%
Revenue beat(16)8
Avg Revenue beat(16)-6.79%
PT rev (1m)4.82%
PT rev (3m)12.99%
EPS NQ rev (1m)15.79%
EPS NQ rev (3m)-45.68%
EPS NY rev (1m)28.33%
EPS NY rev (3m)-1.28%
Revenue NQ rev (1m)-3.8%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)5.66%
Revenue NY rev (3m)-2.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.04
P/S 8.37
P/FCF N/A
P/OCF 73.2
P/B 16.55
P/tB N/A
EV/EBITDA 8344.5
EPS(TTM)-0.04
EYN/A
EPS(NY)1.37
Fwd EY9.06%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)0.21
OCFY1.37%
SpS1.8
BVpS0.91
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.45%
ROE -18.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.49%
FCFM N/A
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
F-Score3
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Debt/EBITDA 576.77
Cap/Depr 426.09%
Cap/Sales 16.83%
Interest Coverage N/A
Cash Conversion 10632.7%
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.43
Altman-Z 3.27
F-Score3
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)372.49%
Cap/Depr(5y)366.77%
Cap/Sales(3y)13.75%
Cap/Sales(5y)36.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y474%
EPS Next 2Y242.97%
EPS Next 3Y149.41%
EPS Next 5Y90.9%
Revenue 1Y (TTM)40.86%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%116.95%
Revenue Next Year105.03%
Revenue Next 2Y76.15%
Revenue Next 3Y61.76%
Revenue Next 5Y43.6%
EBIT growth 1Y-445.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year716.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-261.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y169.71%
OCF growth 3YN/A
OCF growth 5YN/A